 %IdPhases!MetadataAInternalMetadataGroups!Sections+OriginalId#MeasuresGSupplementalFilesò«±‘ IdNameTime$BATreatment Periodó¿‘Ç¿ $	'HAFollow-up Periodó¿‘Ç¿uDesignsTypes0Created"AbstractAuthors>CorporateAuthorCountry)CustomData2DatabaseTypeDOI.FullTextURLISSN2JournalTitle'MedlineIDFParentChildStatus#ParentID>PublicationDate?PublicationYearPubType;ReferenceStudySource6TaStudyDesignTitle3TrialOutcome?FramedQuestionsSources'Digitized:CollectionTypem0123456789
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26Randomized Controlled Triallhd`\XTTherapyòª¦¹Ç¿q2017-02-10T14:50:02.4194672Zá¡•BACKGROUND:  Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis.  OBJECTIVE:  To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials.  METHODS:  Patients who were treatment naive (Comparison of Alemtuzumab and Rebif(Â®) Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 Âµg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36).  RESULTS:  Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS.  CONCLUSION:  Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.Ä½Arroyo GonzÃ¡lez R|Kita M|Crayton H|Havrdova E|Margolin DH|Lake SL|Giovannoni G|}CARE-MS I and II Investigators|EnglandMEDLINEa10.1177/1352458516677589Â©http://dx.doi.org/10.1177/1352458516677589U1477-0970(Electronic)Ã•Multiple sclerosis (Houndmills, Basingstoke, England)óŸ •Ã” ò©·•-2016 Nov 24á¾=Journal Articleò«±‘aMult Scler. 2016 Nov 24;RCTÊAlemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. [CARE-MS I]IPartial Collection!VOriginal Text Task IdNOriginal FR Task IdÂ–Original Error Report - High PriorityÂ’Original Error Report - Low PriorityUpdated/HasFullText*ImportType:EncryptedRefId324390à¡µ<h3><B>Source: <U>Text</U></B></h3><B>Type: <U>Results</U></B><br><br>Attribute <B>"FAMS, Family AND Social Well-Being Score"</B> in Group <B>"Alemtuzuamb 12 mg qd 2yr"</B> contains unparseable/blank Field Value data. Fix the Field Type, data, and/or set to 'Not Reported' if meant to be blank.<br style='mso-data-placement:same-cell;' >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Mean Value: 0.+5<br style='mso-data-placement:same-cell;' >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: SE Value: 0.29<br style='mso-data-placement:same-cell;' ><br>â’™<h3><B>Source: <U>Text</U></B></h3><B>Type: <U>Study</U></B><br><br><font color='green'>This study contains a blank Study Level Source that will not be imported.</font><br style='mso-data-placement:same-cell;' ><br><B>Type: <U>Results</U></B><br><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EDSS" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "FAMS, Total Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "SF-36, MCS Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "SF-36, PCS Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EQ-5D" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EQ-VAS" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br>q2017-08-31T07:46:19.2181567ZExtractAB%2fx813aOHqs%3dÄˆRefId2OriginalName+IsSubGroup;IsIntervention$	.+q1879828_ext-data-31163145256ATotal PopulationÄ˜7Interventions$~ ÄœName+Treatments$	KVò“ˆ±ÈŒ 	Ä¤Phase$	9nBq1879828_ext-data-81221416389aAlemtuzuamb 12 mg qd 2yr$	LX $3ò¯´‰Å¹ $em1879828_ext-data-8122133238ÂInterferon-beta 1a 44 ug tiw 2yr!!Outcomes=Characteristics%Inclusion%ExclusionIUncollectedResults)StudyLevel)GroupLevelEInterventionLevelRowsÃ³1ÅŒ0CellsÅ„'IsOutcome+IsPositive"Category1PDFLocations*Definition+TableNamesTypePopType$!67021818òª¿¥Ç¿ Å°GroupNPopNameStatus$	P)	.+à£)Randomized	NR $PxV	LXË­ Æ€Number$	@SÄ~×¡ò€È€5Adverse EventExtras: Appendices, Supplements	NR$USupplementary Table 2-Participant-Participant$!67021821òª¿±Ç¿ $R1Và£ $	@JË­ $	smÓ…×¡ò€È€$USupplementary Table 25Æˆl<RowTypeÆ€840(Method Unit$!68701316ò“¡ $	sPà¢¹)Population Æ”SE$ $	0'0.0460.017Êµ1Participants $	a70.0390.013Ö¡Changeò€È€5Scales/ScoresÛµEuropean Quality of Life-5 Dimensions (EQ-5D) is a generic, standardized, and validated instrument that provides a simple, descriptive profile, and a single index value comprising five dimensions of health: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Health states are converted to utility scores using country-specific value sets describing the preference of the population for one health state over another.Grab-itMeanunits$!68701317ò“¡ $	:Wà¢¹ $	d+0.0610.017Ê© $	HI0.0640.013Ö­ò€‘™È€
$!68701318ò“¡ $Qauà¢¹ $	A]0.0480.015Ë… $	IA0.0750.012×ò€‘•È€
$!68701319ò“¡ $	1'à¢¹ $	d[0.0370.016Ë• $	']0.0470.012Ö¹ò€È€
$!68741307ò ’© $9S.à£ $	SF3.51.4Êµ $	y25.10.94Ö©ò€È€ÍEuropean-Quality of Life-5 Dimensions, Visual Analog Scale (EQ-VAS) captures patientsâ€™ self-rating of current health status using a visual analog scale ranging from 0 to 100 (higher scores represent better QoL).	mm
$!68741308ò ’© $	9Hà£ $(tw5.61.3Ê­ $xDf6.40.94Öµò€‘™È€
$!68741309ò ’© $	!Yà£ $	~@4.21.1Ë‰ $	Ui7.20.88Ö½ò€‘•È€
$!68741310ò ’© $	](à£ $	l=3.61.1Ë™ $	G.0.88Ö½ò€È€=Æ˜|LÆHD@8<40,$!68700327òª¹µÇ¿ $987à£ $	@B1.10.34Ë­ 
$	2F1.30.3×¡ò€È€É™Functional Assessment of Multiple Sclerosis (FAMS) is a validated, patient-reported, MS-specific, multicomponent, quality of life (QoL) questionnaire.$YSupplementary Figure 1$!68700328òª¹µÇ¿ $	Lwà£ 
$	$+1.30.34Ë­ 
$uED1.60.3×¡ò€‘™È€$YSupplementary Figure 1$!68700329òª¹µÇ¿ $	54à£ 
$	871.40.34Ë­ 
$	e41.60.3×¡ò€‘•È€$YSupplementary Figure 1$!68700330òª¹µÇ¿ $	RNà£ 
$	QL0.3Ë­ 
$	Yu1.60.3×¡ò€È€$YSupplementary Figure 1$!68700331òªº™Ç¿ $	1Eà£ 
$	ZT0.320.33Ë­ò€È€$YSupplementary Figure 1$!68700333òªº™Ç¿ $	V#à£ 
$	QU0.70.31Ë­ 
$	y)0.810.28×¡ò€‘•È€$YSupplementary Figure 1$!68700334òªº™Ç¿ $	eDà£ 
$	'70.610.28Ë­ 
$	Z.0.840.31×¡ò€È€$YSupplementary Figure 1$!68701183òªº™Ç¿ $	iUà£ 
$Bil0.160.34Ë­ 
$	]w0.70.32×¡ò€‘™È€$YSupplementary Figure 1$!68700323òª¹‘Ç¿ $	i9à£ 
$	YZ1.30.41Ë­ 
$	Lo	0.34×¡ò€È€$YSupplementary Figure 1$!68700324òª¹‘Ç¿ $	CZà£ 
$	[j1.10.42Ë­ 
$	BI	0.31×¡ò€‘™È€$YSupplementary Figure 1$!68700325òª¹‘Ç¿ $	ITà£ 
$	(j1.20.34Ë­ 
$	PE1.80.34×¡ò€‘•È€$YSupplementary Figure 1$!68700326òª¹‘Ç¿ $	fRà£ 
$	'+1.20.29Ë­ 
$	'n1.80.28×¡ò€È€$YSupplementary Figure 1$!68700311òª·¡Ç¿ $	EIà£ 
$	D10.840.45Ë­ 
$	0x1.70.34×¡ò€È€$YSupplementary Figure 1$!68700312òª·¡Ç¿ $	Wlà£ 
$	!z1.10.4Ë­ 
$	Dh2.10.29×¡ò€‘™È€$YSupplementary Figure 1$!68700313òª·¡Ç¿ $Dà£ 
$	0V1.20.43Ë­ 
$	D*2.10.31×¡ò€‘•È€$YSupplementary Figure 1$!68700314òª·¡Ç¿ $	@Dà£ 
$	*d0.910.36Ë­ 
$	M@1.70.33×¡ò€È€$YSupplementary Figure 1$!68700315òª¸…Ç¿ $	V*à£ 
$	vD0.340.23Ë­ 
$	J20.850.31×¡ò€È€$YSupplementary Figure 1$!68700316òª¸…Ç¿ $	yxà£ 
$	Yf0.640.39Ë­ 
$	Ni1.50.31×¡ò€‘™È€$YSupplementary Figure 1$!68700317òª¸…Ç¿ $	6(à£ 
$	790.430.38Ë­ 
$	KY1.60.31×¡ò€‘•È€$YSupplementary Figure 1$!68700318òª¸…Ç¿ $	(Sà£ 
$	vy0.340.39Ë­ 
$	rb1.40.31×¡ò€È€$YSupplementary Figure 1$!68701182òª¸½Ç¿ $	Juà£ 
$	JC0.57Ë­ 
$	nD2.30.41×¡ò€‘™È€$YSupplementary Figure 1$!68700319òª¸©Ç¿ $	)Tà£ 
$	+20.810.61Ë­ 
$	2j1.90.44×¡ò€È€$YSupplementary Figure 1$!68700321òª¸©Ç¿ $	Y~à£ 
$	!.1.20.57Ë­ 
$9wF2.60.44×¡ò€‘•È€$YSupplementary Figure 1$!68700322òª¸©Ç¿ $	!Aà£ 
$	&k1.20.48Ë­ 
$	sv1.80.44×¡ò€È€$YSupplementary Figure 1$!68701178òª®¥Ç¿ $	8Aà¡• 
$	:D3.561.94Ê© 
$	hW7.691.56Ö­ò€È€Û…Functional Assessment of Multiple Sclerosis (FAMS) is a validated, patient-reported, MS-specific, multicomponent, quality of life (QoL) questionnaire. || Total score is the sum of 44 scored items from six clinically relevant scales: mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, and family/social well-being. Total scores range from 0 to 176, with higher scores representing better functioning.$!68701179òª®¥Ç¿ $	elà¡• 
$	xK3.941.81Ê™ 
$	K29.131.44Ö½ò€‘™È€$!68701180òª®¥Ç¿ $	GFà¢… 
$	Or5.131.87Ë 
$	IC9.51.44×…ò€‘•È€$!68701181òª®¥Ç¿ $	XRà£ 
$	5B4.131.69Ë 
$	Dm!1.37×ò€È€9Æ˜|LÆHD@8<+TableNames0,$!68700353ò°¾± $	qhà£ ÆœSD,($$E~F-0.910.59Ë­ $	vf1.79.5×¡ò€‘•È€ĞShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL).$USupplementary Table 1$!68700354ò°¾±  $	Jfà£ $	#.-0.810.89Ë­ $	hG0.210.23×¡ò€È€$USupplementary Table 1
$!68700355ò°¿‰ "$	yFà£ $	6=1.28.49Ë­ $	B:2.68.34×¡ò€‘•È€$USupplementary Table 1
$!68700356ò°¿‰ "$	Khà£ $WIf2.28.94Ë­ $	j#	9.36×¡ò€È€$USupplementary Table 1$!68701184òª®±Ç¿ "$	CAà¡± $	4G3.10.73Êµ $	GZ2.90.58Ö½ò€‘•È€Ñ½Short-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary$!68701313òª®±Ç¿ "$	v#à¡• $+f)2.70.82Ê© $h&D2.70.63Ö­ò€È€Ü­Short-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary (MCS); an aggregate score comprising the eight scales emphasizing the mental health, role-emotional, social functioning, and vitality [i.e. energy level/tiredness] scales.)Æ Â„TÆ˜PLH@84$!67021755òª»©Ç¿ $$	j2à£ Æ Percent0,($	z235.2Ë­ $	i032.6×¡ò€È€à°™Short-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary (MCS); an aggregate score comprising the eight scales emphasizing the mental health, role-emotional, social functioning, and vitality [i.e. energy level/tiredness] scales. Clinically meaningful worsening and improvement on the summary measures were defined as >=5-point decrease and increase from baseline norm-based scores, respectively. The 5-point cutoff was based on half a SD, which represents a minimally important difference, and has been used in other studies of MS-related QoL.$!68700341ò˜ˆµ ($	X&à£ $	qY1.310.32Ë­ $	X51.99.27×¡ò€‘•È€ $USupplementary Table 1$!68700342ò˜ˆµ *$	dZà£ $	1(1.89.48Ë­ $	n91.79.83×¡ò€È€"$USupplementary Table 1$!68701314òª®½Ç¿ *$	W[à¡• $	vP1.10.58Êµ $	f33.30.49Ö½ò€‘•È€ÚShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Physical Component Summary (PCS); an aggregate of the eight scales emphasizing the physical function, role-physical, bodily pain, and general health scales.$!68701315òª®½Ç¿ *$	DMà¢¹ $	Nb1.50.37Ê© $	Y'2.40.52Ö­ò€È€$!67021752òª»Ç¿ *$	//à£ $	6G23.5Ë­ $	1u30.5×¡ò€È€à­¹Short-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Physical Component Summary (PCS); an aggregate of the eight scales emphasizing the physical function, role-physical, bodily pain, and general health scales. Clinically meaningful worsening and improvement on the summary measures were defined as >=5-point decrease and increase from baseline norm-based scores, respectively. The 5-point cutoff was based on half a SD, which represents a minimally important difference, and has been used in other studies of MS-related QoL.$!68700349ò…›±t *$	z)à£ $	f$0.37.69Ë­ $	W:1.76.86×¡ò€‘•È€"$USupplementary Table 1$!68700350ò…›±t *$	E@à£ $	fd0.69.27Ë­ $	7c1.37.99×¡ò€È€"$USupplementary Table 1$!68700343óŒŠÅ´ *$	Oeà£ $	PD2.311.32Ë­ $	cC1.49.95×¡ò€‘•È€"$USupplementary Table 1$!68700344óŒŠÅ´ *$	o3à£ $3tg1.412.76Ë­ $A)T11.11×¡ò€È€"$USupplementary Table 1$!68700351ò…›½t *$	GQà£ $	pX1.79.89Ë­ $FRv3.48.87×¡ò€‘•È€"$USupplementary Table 1$!68700352ò…›½t *$	BGà£ $	yz	10.44Ë­ $5M23.29.42×¡ò€È€"$USupplementary Table 1$!68700345ò±‰ *$	kvà£ $	kI1.910.41Ë­ $	zJ2.48.69×¡ò€‘•È€"$USupplementary Table 1$!68700346ò±‰ *$	OKà£ $	=p1.310.84Ë­ $vla2.410.36×¡ò€È€"$USupplementary Table 1$!68700347ò˜‰ *$	s/à£ $	E!0.99.73Ë­ $	lX2.58.65×¡ò€‘•È€"$USupplementary Table 1$!68700348ò˜‰ *$	+Cà£ $	2u1.310.73Ë­ $	1Y2.110.01×¡ò€È€"$USupplementary Table 10#)Æ¤ÂˆXÆœCIsCharacteristicLD<8$!46444828òµƒ ,$	cbà£ $	w:	0.79Ë­ $	Oz	0.81×¡ó¾½©Ç¿ÂExpanded Disability Status Scale$!68700357ò“¡ .$	C:à£ $	(h0.780.19Ë­ $	Pn0.770.21×¡ó¾½©Ç¿,$!68739552ò ’© .$	kdà£ $	1j75.9415.89Ë­ $	y!75.817.87×¡ó¾½©Ç¿($!68700306òª®¥Ç¿ .$	y(à£ $	hy134.227.61Ë­ $	C3133.427.65×¡ó¾½©Ç¿ -Æ¨ÂŒ\ Æ PH@<$!48856398ò´¸¥ 0$v:#à£ $	cj	1.32Ë­ $	B72.11.36×¡!Durationó¾½©Ç¿=Medical HistorymTime since initial episodes	yr)Æ¨ÂŒ\Æ TPH@<$!68700305òŠ¹ 4$	.Và£ $	!G1.80.83Ë­ $	]11.80.81×¡ó¾½©Ç¿4$!68700335òª®±Ç¿ 6$	bmà£ $dy]45.411.26Ë­ $	4D46.510.95×¡ó¾½©Ç¿$!68700336òª®½Ç¿ 6$	aJà£ $	ma48.38.41Ë­ $	N[47.98.62×¡ó¾½©Ç¿<Æ¨ÂŒ@P$!67021497òª«¡Ç¿Æ‘1Demographics$!67021494òª«•Ç¿Æ‘$!67021491òª«‰Ç¿Æ‘$!68701174ò’¿•ÈŒÆ‘$!68701326ò“ˆµÈŒÆ‘$!67021488óº‹™Æ‘@Æ¨ÂŒ@($!67021506òª¬…Ç¿D#!Æ¨ÂŒ@Stats+TimePointsX>UncollectedType1SubgroupName$!68700298ò’ˆ¥ÈŒUUncollectedContinuous)ContinuousÂœò’Œ½ÈŒ$!68700299ò’ˆ¥ÈŒò’ÈŒ
$!68701176ò’¿ÈŒò’Œ½ÈŒ
$!68701177ò’¿ÈŒò’ÈŒ
$!68700295ò’ˆ™ÈŒò’Œ½ÈŒ
$!68700296ò’ˆ™ÈŒò’ÈŒ
$!68700292ò’ˆÈŒò’Œ½ÈŒ
$!68700293ò’ˆÈŒò’ÈŒLCÆ¸Âœ`lP$!21514956æ°¥1Study Design 	Æ¸Value$qDrugString$!21514960ğ¡• $K	No
$!21523959ğ£¹­ $zUOpen Blinded Endpoint
$!39906888ğ¦”½ $u-NCT00530348-LookupTable
$!39906893ğ±… $w3Æ¼Â pdTP$!21514922ğ¥¹ Æ¼<3IsDefaultPop$[à£AStudy PopulationIntegerÇ€Â¤thX$!21514938ğ¨ Ç€@HL$cÌ™à£$!21514940ğ¨‘ $aÖµà£
$!21514942ò®·¥Â† Ç€@ HL$sà£Ç€Â¤thX$!61885785ğŸµ $==Journal Article9Study Document$!21519514ğ¡½ Ç€-FundingType=InstitutionType$y(ğ¢‰*á„‘5Study FundingFunding$!21514966ğ‘¯…  $	@8Ï‰Multiple Sclerosis, Relapsing-Remitting, Active|>= 2 relapses in prior 2 years|>= 1 relapse in the prior year|18â€“50 years of age|Baseline expanded disability status scale (EDSS) score <= 3|Multiple Sclerosis (MS) symptom onset within 5 years|)Study Data
$!21517349ğ£»­ "$	NMÃPrevious use of disease-modifying therapy (DMT)|
$!61886395ò†¶•Ç "$.%CARE-MS I5Study SettingÇˆÂ¬|p`8$!21516048ğ¨ª Çˆ$	q$eStudy Phase Randomization%UnitValue!Baseline$!68737533ò¶Ÿ±ÈŒ ($6YesIAll Arms ExtractedxÇˆ|`Â¬$!21514940 ÇˆHXPT$*Öµà£ ÇˆH(XPT$	2~Ï64.6×¡ $FÇ©65.2Ë­ ğ¨‘$!21514938 $)Ì™à£ $oÈ•35.4×¡ $VÄ…34.8Ë­ ğ¨Çˆ|`\Â¬$!21514922 ÇˆHX$]à£ $	h(×¡ $@Ë­ğ¥¹$!21514942 $(à£ $	:V×¡ $	x6Ë­ ò®·¥Â†$!21517413 ÇˆX$4È­Patients recevied alemtuzumab 12mg/day intravenous (IV) once daily on 5 consecutive days at baseline and on 3 consecutive days at Month 12. $1Å±Patients received interferon-beta 1a (IFNB-1a) 44 ug subcutaneously (SC) three times weekly.ğ‘ƒ™Çˆ|`8Â¬$!21514936 ÇˆH,XPT$	'KÂ…8.03×¡ $O33.28.48Ë­æ±¥Rowsòª¦¹Ç¿Â— !ÇŒdRangesAMTypeL<LeftRight$	2AIAssociationMeasure t<LowLHigh	CIÅ½d0.078.44=Mean Difference4.25$	hW$	:D Ç¤|&POperatorPValue$	r9PValue<0.05$	hW$	:D$	hW$	:D $	4w0.05$	K2$	xK$	K2$	xK $ERf Å½1.33
8.995.16$	K2$	xK $	1t Å½
0.67
8.164.42$	IC$	Or $eGj0.05$	IC$	Or$	IC$	Or $	'y0.05$	Dm$	5B$	Dm$	5B $	[3 Å½
0.69
6.993.84$	Dm$	5B $	Kg0.05$	M@$	*d$	M@$	*d $	k40.05$	D*$	0V$	D*$	0V $	3'0.05$	Dh$	!z$	Dh$	!z $TE/0.05$	0x$	D1$	0x$	D1 $	i*0.05$	rb$	vy$	rb$	vy $	1D0.05$	KY$	79$	KY$	79 $kmR0.05$	Ni$	Yf$	Ni$	Yf $	VR0.05$	BI$	[j$	BI$	[j Ç¬Â„7IsSignificant$	Co0.05$	f3$	vP$	f3$	vP !Ç°Âˆ p$AY*=0.14)Odds Ratio1.39$	1u$	6G $	p30.880.97$	i0$	z2 $	x@0.2392$	X5$	qY$	X5$	qY $	JN0.6306$	n9$	1($	n9$	1( $	+]0.4249$	cC$	PD$	cC$	PD $	8*0.8202$A)T$3tg$A)T$3tg $	9u0.2255$	zJ$	kI$	zJ$	kI $	Dz0.085$vla$	=p$vla$	=p $	sl0.0727$	lX$	E!$	lX$	E! $	*n0.8019$	1Y$	2u$	1Y$	2u $	cm0.0036$	W:$	f$$	W:$	f$ $	ta0.2423$	7c$	fd$	7c$	fd $F!/0.0117$FRv$	pX$FRv$	pX $huH0.108$5M2$	yz$5M2$	yz $	yK0.0085$	vf$E~F$	vf$E~F $	i!0.7179$	hG$	#.$	hG$	#. $	Ep0.0317$	B:$	6=$	B:$	6= $	3#0.9619$	j#$WIf$	j#$WIf $	qK0.05$	Ui$	~@$	Ui$	~@ $	uj0.05$	G.$	l=$	G.$	l= 	[ReferencePackageFileId"FileNameï¿½USupplement Data 1.pdf ï¿½USupplement Data 2.pdf